Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.
Read More…
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone514-484-4483
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$12.30 million
Profitability
Miscellaneous
Employees27
Next Earnings Date8/8/2019 (Estimated)
OptionableNot Optionable
Knight Therapeutics (TSE:GUD) Frequently Asked Questions
What is Knight Therapeutics' stock symbol?
Knight Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD."
How were Knight Therapeutics' earnings last quarter?
Knight Therapeutics Inc (TSE:GUD) released its earnings results on Thursday, May, 9th. The company reported $0.04 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.01. The firm had revenue of $2.96 million for the quarter, compared to the consensus estimate of $3.06 million. View Knight Therapeutics' Earnings History.
When is Knight Therapeutics' next earnings date?
What price target have analysts set for GUD?
2 Wall Street analysts have issued 12-month price targets for Knight Therapeutics' shares. Their forecasts range from C$10.00 to C$10.25. On average, they anticipate Knight Therapeutics' stock price to reach C$10.13 in the next twelve months. This suggests a possible upside of 33.2% from the stock's current price. View Analyst Price Targets for Knight Therapeutics.
What is the consensus analysts' recommendation for Knight Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Knight Therapeutics.
Has Knight Therapeutics been receiving favorable news coverage?
Media headlines about GUD stock have been trending somewhat positive on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Knight Therapeutics earned a news impact score of 1.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Knight Therapeutics.
Who are some of Knight Therapeutics' key competitors?
Some companies that are related to Knight Therapeutics include Hikma Pharmaceuticals (HIK), Evotec (EVT), Aphria (APHA), Hexo (HEXO), HEXO (HEXO), OrganiGram (OGI), CannTrust (TRST), Green Organic Dutchman (TGOD), Flowr (FLWR), Supreme Cannabis (FIRE), HLS Therapeutics (HLS), Benchmark (BMK), ICC Labs (ICC), Depomed (ASRT) and WeedMD (WMD).
What other stocks do shareholders of Knight Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Knight Therapeutics investors own include Constellation Software (CSU), Mondi (MNDI), Bombardier, Inc. Class B (BBD.B), Spin Master (TOY), Extendicare (EXE), Allena Pharmaceuticals (ALNA), Franco Nevada (FNV), Exxon Mobil (XOM), Aurora Cannabis (ACB) and Alimentation Couche-Tard (ATD.B).
Who are Knight Therapeutics' key executives?
Knight Therapeutics' management team includes the folowing people:
- Mr. Jonathan Ross Goodman BA, LLB, MBA, CEO & Director (Age 50)
- Ms. Samira Sakhia C.A., C.P.A., M.B.A., MBA, BCom, CPA, DPA, CA, Pres, CFO & Director (Age 50)
- Mr. Michel Loustric, Pres of Knight Barbados
- Ms. Amal Khouri, VP of Bus. Devel.
- Ms. Jody Engel, Director of Bus. Devel.
How do I buy shares of Knight Therapeutics?
Shares of GUD and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Knight Therapeutics' stock price today?
One share of GUD stock can currently be purchased for approximately C$7.60.
How big of a company is Knight Therapeutics?
What is Knight Therapeutics' official website?
How can I contact Knight Therapeutics?
The company can be reached via phone at 514-484-4483.
MarketBeat Community Rating for Knight Therapeutics (TSE GUD)
MarketBeat's community ratings are surveys of what our community members think about Knight Therapeutics and other stocks. Vote "Outperform" if you believe GUD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GUD will underperform the S&P 500 over the long term. You may vote once every thirty days.
